A detailed history of Grimes & Company, Inc. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 10,000 shares of IBRX stock, worth $44,900. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Previous 10,000 -0.0%
Holding current value
$44,900
Previous $63,000 41.27%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 19, 2023

BUY
$1.53 - $6.41 $15,300 - $64,100
10,000 New
10,000 $27,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Grimes & Company, Inc. Portfolio

Follow Grimes & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.